BeOne Medicines (BEIGF) Other Non-Current Liabilities (2015 - 2026)

BeOne Medicines (BEIGF) has 12 years of Other Non-Current Liabilities data on file, last reported at $82.0 million in Q1 2026.

• Other Non-Current Liabilities for Q1 2026 came in at $82.0 million, up 24.87% year-over-year; the trailing twelve-month figure through Mar 2026 was $82.0 million (up 24.87% YoY), and the FY2025 annual result was $80.2 million, up 20.24% from the prior year.
• Other Non-Current Liabilities grew to $82.0 million in Q1 2026 per BEIGF's latest filing, from $80.2 million in the prior quarter.
• Over five years, Other Non-Current Liabilities peaked at $180.5 million in Q4 2022 and troughed at $42.0 million in Q3 2023.
• A 5-year average of $63.5 million and a median of $51.5 million in 2024 frame the typical range for Other Non-Current Liabilities.
• The sharpest annual moves came in 2022 and 2023: Other Non-Current Liabilities surged 232.77% in 2022, then slumped 71.85% in 2023.
• A 5-year view of Other Non-Current Liabilities shows it stood at $180.5 million in 2022, then tumbled by 71.85% to $50.8 million in 2023, then jumped by 31.34% to $66.7 million in 2024, then advanced by 20.24% to $80.2 million in 2025, then increased by 2.13% to $82.0 million in 2026.
• Business Quant data shows BEIGF's Other Non-Current Liabilities at $82.0 million in Q1 2026, $80.2 million in Q4 2025, and $64.1 million in Q3 2025.